Compare Abbott Laboratories (ABT) vs iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs iShares S&P GSCI Commodity-Indexed Trust ETF — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while iShares S&P GSCI Commodity-Indexed Trust ETF trades at $29.94. The key difference: Abbott Laboratories pays a 2.63% dividend while iShares S&P GSCI Commodity-Indexed Trust ETF pays none, and iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | GSG | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $136.62 | $34.77 |
52-Week Low | $82.57 | $22.06 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
GSG trades at $28.89, up 1.83% today, with a bullish technical signal but mixed moving averages and neutral oscillators. Recent news highlights institutional interest, with JPMorgan Chase increasing its stake by 224.3% in Q3 2025 (SEC filing, 2026-04-07). Commodity ETFs like GSG are gaining attention amid inflation fears and supply constraints, as noted by Zacks Investment Research (2026-04-07).
The outlook for GSG is supported by strong commodity market trends and institutional accumulation, but risks include volatility from geopolitical events and inflation shifts. Key support sits at $28, with resistance near $29. Wall Street sentiment is cautiously optimistic due to macroeconomic tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →
